GHRP-2-asetaatti

📦 Jokainen tilaus on katettuna meidän Reshipment Assurance Policy -politiikkamme piiriin — jos lähetyksesi ei saavu 20 arkipäivässä, lähetämme uuden.

What Is GHRP-2 Acetate?

GHRP-2 (Growth Hormone Releasing Peptide 2), also known as Pralmorelin or by its original developmental code KP-102, is a 6-amino-acid synthetic hexapeptide and one of the canonical first-generation members of the growth hormone secretagogue (GHS) peptide class. It was developed shortly after GHRP-6 in the same Bowers structure-activity-relationship programme at Tulane University, with a focus on increasing per-mg potency relative to the parent compound while preserving the GHS-R1a-selective receptor profile. The acetate counterion is used in research-grade lyophilization because it improves long-term peptide stability and aqueous solubility without altering pharmacology.

The well-characterised sequence is D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH₂, molecular weight 817.97 Da, empirical formula C₄₅H₅₅N₉O₆. The structural innovation relative to GHRP-6 is the introduction of D-2-naphthylalanine (D-2-Nal) at position 2 in place of D-Trp — the more lipophilic naphthyl ring increases GHS-R1a affinity and produces approximately 2–3-fold greater per-mg GH-releasing potency in published research. The two D-amino-acid substitutions (D-Ala at position 1, D-Phe at position 5) confer protease resistance. Notably, in Japan GHRP-2 (under the name Pralmorelin Hydrochloride / GHRP Kaken) was approved as a single-use intravenous diagnostic agent for adult growth hormone deficiency testing — one of the only GHS peptides to reach any form of clinical approval. GHRP-2 remains not approved by the FDA, EMA, MHRA, or any other Western regulator for therapeutic use. The research-grade GHRP-2 acetate sold here is supplied vain laboratoriotutkimuskäyttöön and is not intended for human or veterinary administration.

Mechanism of Action — GHS-R1a Receptor Agonism with Enhanced Potency

What makes GHRP-2 mechanistically distinctive among first-generation growth hormone secretagogues is the combination of high GHS-R1a affinity with a relatively short plasma half-life, producing a sharper and more reproducible GH pulse in published research:

• GHS-R1a receptor agonism on somatotrophs — GHRP-2 binds the growth hormone secretagogue receptor type 1a (GHS-R1a, the ghrelin receptor) on anterior-pituitary somatotrophs. Receptor activation couples to Gα_q/11 and phospholipase C, raising intracellular calcium and triggering exocytosis of GH-containing vesicles. The substitution of D-2-Nal at position 2 produces approximately 2–3-fold higher receptor occupancy at equivalent doses compared with GHRP-6 in radioligand-binding assays, translating into a larger GH pulse per unit dose.
• Somatostatin tone suppression — Like other GHRPs, GHRP-2 acts both at the somatotroph and at hypothalamic neurons that release somatostatin. By suppressing tonic somatostatin inhibition simultaneously with stimulating somatotroph release, the peptide produces a larger net GH pulse than direct pituitary stimulation alone would predict. This dual action is the canonical mechanism of the GHRP class and underlies the synergy with GHRH analogs described below.
• Synergy with GHRH-receptor agonists — The GHS-R and GHRH-R pathways converge intracellularly but use different second-messenger systems (PLC/IP₃/Ca²⁺ vs adenylyl cyclase/cAMP/PKA), so GHRP-2 and GHRH analogs produce additive or synergistic GH release when combined. The canonical research protocol pairs GHRP-2 with a GHRH analog such as Sermorelin tai CJC-1295 DAC:lla for maximal pulsatile GH research stimulus. The “GHRP-2 + GHRH” challenge is also the basis for the Japanese clinical use of Pralmorelin in GH-deficiency diagnostic testing.

GHRP-2 produces a smaller appetite signal than GHRP-6 in head-to-head rodent and human research — the D-2-Nal substitution at position 2 reduces but does not eliminate the orexigenic activity inherited from ghrelin-receptor agonism. The cortisol and prolactin signals remain present at levels comparable to GHRP-6, which is the principal research-relevant confound that newer receptor-selective analogs (Ipamorelin) were designed to eliminate. Plasma half-life is approximately 15–20 minutes — shorter than GHRP-6 (~30–60 min) — which produces a sharper and more reproducible GH pulse but requires more frequent dosing for sustained-stimulus research protocols.

Julkaistut tutkimussovellukset

GHRP-2 is used in laboratory research contexts that investigate:

• Growth hormone axis pharmacology — pulsatile GH dynamics, somatotroph dose-response, comparative GHS potency assays; benchmark high-potency first-generation GHS in published GH-axis literature (Bowers, J Clin Endocrinol Metab; Ghigo et al., J Clin Endocrinol Metab)
• GH-deficiency diagnostic research — GHRP-2 stimulation testing for adult GH deficiency (the Japanese clinical use case), GHRP-2 + GHRH combined-challenge testing, somatotroph reserve characterisation in preclinical models
• Pituitary function research — GH reserve testing, somatotroph hypertrophy / hyperplasia, mechanism-of-action research for novel GH secretagogues
• Cachexia and wasting syndrome research — tumour-bearing rodent cachexia, COPD-associated wasting, aging-related sarcopenia models; smaller appetite signal than GHRP-6 makes GHRP-2 useful when food-intake is a confound
• Ghrelin-axis pharmacology — reduced but non-zero appetite signal; useful research arm for separating GHS-R-mediated appetite from GH-axis effects
• Comparative GHS research — head-to-head benchmarking against GHRP-6 (first-generation sibling), Ipamorelin (third-generation receptor-selective), hexarelin, and orally-active small-molecule GHS such as MK-677
• Combined GHRP + GHRH research — canonical “GHRP-2 + GHRH” synergistic protocol for maximal GH-pulse research stimulus, pairing GHRP-2 with Sermorelin tai CJC-1295 DAC:lla.

For broader context on where GHRP-2 fits within the growth-axis peptide landscape, see GHRP-6 as the first-generation sibling, Ipamorelin as the receptor-selective newer analog, and CJC-1295 DAC:lla as the canonical synergistic GHRH partner. Browse the full tutkimuspeptidien luettelo liittyvistä yhdisteistä.

Saatavat vahvuudet ja pitoisuudet

MedsBase stocks GHRP-2 Acetate in two lyophilized vial sizes calibrated to typical research protocol lengths. Each strength is available in 10-vial or 20-vial pack formats with full reconstitution guidance:

Both strengths are the same chemical form (lyophilized acetate-salt powder, 99%+ HPLC purity). Higher-mg vials require smaller reconstitution volumes per unit dose, which is useful when researchers want to minimise injection volume in rodent protocols. Because GHRP-2 dose ranges are in the 100–500 mcg per administration regime, a single 5 mg vial supports many weeks of research at typical doses.

How It Compares — GHRP-2 vs GHRP-6

GHRP-2 and GHRP-6 are the two canonical first-generation hexapeptide growth hormone secretagogues from the Bowers laboratory programme. They share the same receptor (GHS-R1a) and the same six-residue hexapeptide architecture, differing primarily in the amino acid at position 2 — D-2-naphthylalanine in GHRP-2 versus D-tryptophan in GHRP-6. This single substitution accounts for most of the pharmacological differences observed in published research.

For research where appetite stimulation is part of the target endpoint (cachexia models, food-intake studies), GHRP-6 is the conventional choice because the orexigenic signal is stronger. For research where the appetite confound is a concern but cortisol/prolactin tolerability is acceptable, GHRP-2 produces a sharper GH pulse with less feeding-behaviour interference. For the cleanest possible GH-axis pharmacology where cortisol and prolactin must be controlled, Ipamorelin (third-generation selective analog) is the receptor-selective alternative.

Säilytys ja liuotus

Ennen liuotusta: store lyophilized vials refrigerated at 2–8 °C in original packaging for short-term working stock. For unopened long-term storage, freeze at −20 °C. Lyophilized GHRP-2 acetate is stable under refrigeration for up to 24 months and at −20 °C for up to 36 months. Avoid freeze-thaw cycles on the lyophilized powder.

Uudelleenliuotusmenettely: inject bacteriostatic water down the side wall of the peptide vial (not directly onto the lyophilized cake). For a 5 mg vial, 2.0 mL of bacteriostatic water yields a 2.5 mg/mL working concentration — 0.04 mL delivers a 100 mcg research dose; 0.1 mL delivers 250 mcg. Swirl gently — do ei ravistele — ja anna 2–5 minuuttia täydelliseen liukenemiseen. Oikein uudelleenliuotettu liuos tulisi olla kirkas ja väritön.

Uudelleenliuotuksen jälkeen: store refrigerated at 2–8 °C and use within 30 days for optimal stability. Do not freeze the reconstituted solution — freeze-thaw cycles degrade peptide integrity. Discard any vial showing cloudiness, precipitate, or discolouration.

Usein Kysytyt Kysymykset

What is GHRP-2 used for in research?

GHRP-2 is used in laboratory research investigating the growth hormone axis, pulsatile GH release dynamics, somatotroph dose-response characterisation, GH-deficiency diagnostic protocols, ghrelin-axis pharmacology, cachexia and wasting syndrome models, and combined GHRP + GHRH synergistic GH-release protocols. It is the most potent first-generation GHS research peptide on a per-mg basis. The research-grade GHRP-2 sold here is ei FDA-approved (except for the diagnostic indication in Japan) and is supplied strictly for laboratory research use only.

How is GHRP-2 different from GHRP-6?

Both are first-generation hexapeptide growth hormone secretagogues that act on the same GHS-R1a receptor, but they differ in the amino acid at position 2 — D-2-naphthylalanine in GHRP-2 versus D-tryptophan in GHRP-6. This single substitution makes GHRP-2 about 2–3× more potent on a per-mg basis and produces a smaller appetite signal. Both peptides retain the modest cortisol/prolactin signal that newer receptor-selective analogs (such as Ipamorelin) were designed to eliminate. Plasma half-life is shorter for GHRP-2 (~15–20 min) vs GHRP-6 (~30–60 min).

What is the difference between GHRP-2 and Pralmorelin?

They are the same compound under different names. “GHRP-2” is the research-literature designation; “Pralmorelin” is the international nonproprietary name (INN); “KP-102” was the original Kaken Pharmaceutical developmental code. The compound was approved in Japan under the Pralmorelin name as a single-use intravenous diagnostic test for adult growth hormone deficiency — the only Western-style regulatory approval of any GHRP-series peptide to date.

What is the typical GHRP-2 research dose?

Published preclinical protocols typically use 100–500 mcg per administration, given subcutaneously 1–3 times daily for 2–12 week research cycles. A 5 mg vial reconstituted with 2.0 mL bacteriostatic water yields 2.5 mg/mL — 0.04 mL equals 100 mcg, 0.1 mL equals 250 mcg. The Japanese diagnostic-test dose is 100 mcg intravenously as a single administration.

Is GHRP-2 FDA approved?

No. GHRP-2 is not approved by the FDA, EMA, MHRA, or any other Western regulator for human therapeutic or diagnostic use. It is approved in Japan under the name Pralmorelin Hydrochloride / GHRP Kaken as a single-use intravenous diagnostic agent for adult growth hormone deficiency testing. All GHRP-2 sold by research-use-only suppliers outside Japan is for laboratory investigation and should not be administered to humans.

How should GHRP-2 Acetate be stored?

Lyofiloituja pulloja: lyhytaikainen käyttövarasto jääkaapissa 2–8 °C:ssa tai pitkäaikainen säilytys avaamattomille pulloille −20 °C:ssa. Uudelleenliuotettu liuos: jääkaapissa 2–8 °C:ssa, käytettävä 30 päivän kuluessa. Älä jäädytä uudelleenliuotettua liuosta - jäätymis-lämmitysjaksot heikentävät peptidin laatua. Suojaa aina suoralta valolta.

How do I reconstitute GHRP-2?

Noudata yllä kuvattua uudelleenliuotusmenettelyä. Lisää bakteriostaattista vettä pullon sivuseinää pitkin (ei suoraan lyofiloituun kuoreen), kiertoile hellästi ja anna 2–5 minuuttia täydelliseen liukenemiseen. Älä ei shake the vial. A correctly reconstituted solution is clear and colourless. For a 5 mg vial + 2.0 mL diluent, the working concentration is 2.5 mg/mL.

Mitä vahvuuksia MedsBase pitää varastossaan?

MedsBase carries GHRP-2 Acetate in 5 mg and 10 mg lyophilized vials. Each strength is available in 10-vial or 20-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request.

Why is GHRP-2 more potent than GHRP-6?

The structural difference is the amino acid at position 2 of the hexapeptide — D-2-naphthylalanine in GHRP-2 versus D-tryptophan in GHRP-6. The naphthyl ring is more lipophilic and slightly larger than the indole ring of tryptophan, producing tighter binding to the hydrophobic pocket of the GHS-R1a receptor. Radioligand-binding assays show approximately 2–3-fold higher receptor occupancy at equivalent doses, which translates into a larger GH pulse per unit dose in published preclinical and clinical research.

Can GHRP-2 be paired with a GHRH analog in research?

Yes — this is the canonical synergistic GH-pulse protocol and the basis of the Japanese clinical GH-deficiency diagnostic test. GHRP-2 activates GHS-R1a (PLC/IP₃/Ca²⁺ signalling) while GHRH analogs such as Sermorelin tai CJC-1295 DAC:lla activate GHRH-R (adenylyl cyclase/cAMP/PKA signalling). The two pathways converge on somatotrophs but use different second-messenger systems, producing additive or synergistic GH release when combined.

Does GHRP-2 cause side effects in research?

The principal on-target effects are GH release and (modest) appetite stimulation. Off-target findings include modest cortisol and prolactin increases — the principal research-relevant confound for clean GH-axis studies — comparable in magnitude to GHRP-6. Transient flushing or local injection-site reactions are reported. At high doses, GHS-R-mediated effects on cardiac function and blood pressure can be observed. The cortisol/prolactin signal is the main reason newer-generation selective analogs such as Ipamorelin were developed.

What is the half-life of GHRP-2?

In preclinical and clinical research, GHRP-2 has a plasma half-life of approximately 15–20 minutes following subcutaneous or intravenous administration — somewhat shorter than GHRP-6 (~30–60 min). The shorter half-life produces a sharper, more reproducible GH pulse that is useful for diagnostic and dose-response research, but requires more frequent dosing for sustained-stimulus research protocols.

How long does GHRP-2 take to show effects in preclinical research?

Acute GH pulses are detectable within 10–20 minutes of subcutaneous or intravenous administration and peak within 30–45 minutes — faster onset than GHRP-6 due to higher GHS-R1a affinity. Appetite-stimulation effects on food intake are smaller and slower to develop than with GHRP-6. Downstream effects on IGF-1 production and tissue-level GH-axis signalling accumulate over 1–4 weeks of regular dosing.

Can I order GHRP-2 for international shipping?

Yes. MedsBase ships GHRP-2 worldwide from our dedicated peptide shipping network. Peptide-only orders qualify for our standalone peptide shipping service. All orders ship in temperature-controlled packaging with full tracking and are covered by our Reshipment Assurance Policy -politiikkamme piiriin.

Other Peptides for Growth-Axis, GH-Release, and Anabolic Research

• GHRP-6 — First-generation hexapeptide sibling — stronger appetite signal, longer half-life
• Ipamorelin — Third-generation selective GHS pentapeptide — clean GH pulse without cortisol/prolactin
• CJC-1295 DAC:lla — Long-acting GHRH analog — canonical synergistic GHRH partner
• Sermorelin — Shorter-acting GHRH(1-29) analog — natural GH-pulse research
• IGF-1 LR3 — Long-arginine recombinant IGF-1 analog — downstream of GH/IGF axis

Lisälukemista

Lisää vaihtoehtoja Peptideissä

Luokiteltu MedsBase-tilausmäärän mukaan — mitä muut asiakkaat tässä kategoriassa valitsevat.

BPC-157

US$115.00 – US$705.00Fourchette de prix : US$115.00 à US$705.00

Retatrutide

US$310.00 – US$6,515.00Fourchette de prix : US$310.00 à US$6,515.00

BAC Vesi (Bakteriostaattinen vesi)

US$50.00 – US$150.00Fourchette de prix : US$50.00 à US$150.00

NAD⁺

US$210.00 – US$1,975.00Fourchette de prix : US$210.00 à US$1,975.00